Clinical Trials Logo

Filter by:
NCT ID: NCT01127633 Terminated - Alzheimer's Disease Clinical Trials

Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease

EXPEDITION EXT
Start date: December 2010
Phase: Phase 3
Study type: Interventional

This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).

NCT ID: NCT01124344 Terminated - Major Depression Clinical Trials

Safety and Pharmacology Study of BMS-866949

Start date: May 2010
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to determine whether multiple doses.of BMS-886949 are safe and tolerable

NCT ID: NCT01118455 Terminated - Epilepsy Clinical Trials

Trial to Assess Vagus Nerve Stimulation Therapy vs. Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures

Start date: October 2004
Phase: Phase 4
Study type: Interventional

This is a randomized study designed to compare long-term treatment outcomes in pediatric patients with refractory seizures treated with VNS (Vagus Nerve Stimulation) Therapy versus anti-epileptic drugs (AEDs). Seizure reduction, quality of life measures, and side effect profiles will be evaluated. The results of this study will provide controlled comparative data to better guide physicians in determining the best overall treatment strategy for patients with seizures who have failed initial AED therapy.

NCT ID: NCT01111565 Terminated - Clinical trials for Major Depressive Disorder (MDD)

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Start date: October 4, 2010
Phase: Phase 3
Study type: Interventional

This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an incomplete response to a prospective trial of Escitalopram, and report a treatment history for the current MDD episode of an inadequate response to at least one and no more than three adequate trials of an approved antidepressant other than Escitalopram. An inadequate response is defined as less than a 50% reduction in depressive symptom severity as assessed by the participant's self-report on the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and evaluated by the investigator as part of the participant's medical and psychiatric history. An adequate trial is defined as an antidepressant treatment for at least 6 weeks duration (or at least 3 weeks for combination treatments) at an approved dose as specified in the ATRQ.

NCT ID: NCT01092312 Terminated - Clinical trials for Arthroplasty, Replacement, Knee

Signature Personalised Patient Care System With the Vanguard Knee System Study

Start date: March 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the percentage cases which have ideal mechanical axial alignment using the Vanguard total Knee implant with the Signature cutting blocks is higher than those without the use of Signature when measured immediately post-operatively.

NCT ID: NCT01087593 Terminated - Fibromyalgia Clinical Trials

Estrogens Effect on Pain in Postmenopausal Women Suffering of Fibromyalgia

Start date: August 2001
Phase: N/A
Study type: Interventional

In order to evaluate the potential effects of estrogen treatment in postmenopausal women with fibromyalgia, the investigators used quantitative sensory tests before and after eight weeks of estrogen treatment as compared with placebo treatment.

NCT ID: NCT01085513 Terminated - Clinical trials for Intestinal Abnormalities

Diagnosis of Intestinal Motility by Image Analysis Using Capsule Endoscopy

Start date: February 2009
Phase: N/A
Study type: Interventional

Conventional intestinal manometry is the current gold standard for the evaluation of intestinal motility, and identifies patterns of intestinal dysmotility. However intestinal manometry involves intestinal intubation with consequent discomfort for the patients, and requires considerable technical expertise and knowledge for interpretation of the data. Hence, to date this method has limited indications and is restricted to very few referral centers around the world. A novel method for evaluation of intestinal motility has been developed based on endoluminal image analysis using the endoscopic PillCam capsule, In contrast to manometry, this technique is minimally invasive, the technical aspects are simple, and the analysis is fully automated by a computer program. The technique has been validated in a group of patients with intestinal dysmotility and healthy subjects, and has demonstrated over 90% sensitivity and specificity. This technique needs now to be validated in a large multinational population, to further develop a robust discrimination algorithm for widespread diagnostic application. Furthermore, whereas manometry only recognizes neuropathic, myopathic and obstructive motor patterns, endoluminal image analysis may identify different categories of patients depending on the clinical presentation and the etiologic factors involved. This study is designed to provide evidence that the algorithm, using images created by PillCam SB2 capsules, is at least as good as small bowel manometry in diagnosing severe dysmotility.

NCT ID: NCT01079169 Terminated - Spinal Cord Injury Clinical Trials

Effect of Cranberry Capsules on Urinary Infection Rates in Spinal Cord Injured Patients During Post Acute Rehabilitation

Start date: March 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to establish whether cranberry capsules reduce rates of urinary tract infections during initial rehabilitation immediately after spinal cord injury.

NCT ID: NCT01065077 Terminated - Acute Heart Failure Clinical Trials

BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

COMPOSE 1
Start date: March 2010
Phase: Phase 2
Study type: Interventional

A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.

NCT ID: NCT01058005 Terminated - Clinical trials for Relapsing Remitting Multiple Sclerosis

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

SURPASS
Start date: March 2010
Phase: Phase 3
Study type: Interventional

This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg). Participants were to be randomized to receive natalizumab, interferon β-1a 44 μg, or glatiramer acetate.